Biogen Says Litifilimab Safety Profile Consistent With No New Safety Signals Identified

Oct 2 (Reuters) - Biogen Inc. BIIB.O:

• BIOGEN’S LITIFILIMAB DEMONSTRATES RAPID AND DURABLE EFFICACY IN NEW 52-WEEK PHASE 2 DATA FROM ONGOING PHASE 2/3 AMETHYST STUDY, REINFORCING ITS POTENTIAL AS A FIRST-IN-CLASS THERAPY FOR CUTANEOUS LUPUS ERYTHEMATOSUS~

• BIOGEN - 27.2% OF PARTICIPANTS ACHIEVE CLEAR OR ALMOST CLEAR SKIN AT WEEK 52 WITH LITIFILIMAB

• BIOGEN - LITIFILIMAB SAFETY PROFILE REMAINS CONSISTENT WITH NO NEW SAFETY SIGNALS IDENTIFIED

• BIOGEN - SERIOUS ADVERSE EVENTS OCCURRED IN 3.4% OF PARTICIPANTS DURING 52-WEEK TREATMENT PERIOD

• BIOGEN - 28.8% OF PARTICIPANTS ACHIEVE 70% OR GREATER REDUCTION IN CLASI A AT WEEK 52

• BIOGEN - 33.7% OF CROSSOVER PARTICIPANTS REPORT CLEAR OR ALMOST CLEAR SKIN AT WEEK 52

Further company coverage: BIIB.O